

ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shiv Sagar Estate, Dr. Annie Besant Road, Worli, Mumbai-400018

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2016

Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com


₹ In Lakhs

Sr. No.	Particulars	Unaudited	Audited	Unaudited	Audited
		3 months ended 30/06/2016	Preceding 3 months ended 31/03/2016	Corresponding 3 months ended in the previous year 30/06/2015	Previous year ended 31/03/2016
1	Income From Operations				
	a Net Sales/ Income from Operations (Net of Excise duty)	4800.91	6840.98	8556.06	32063.07
	b Other Operating Income	109.54	173.32	107.88	559.10
	Total income from Operations (net):-	4910.45	7014.30	8663.94	32622.17
2	Expenditure				
	a Changes in inventories of finished goods, work-in-progress and stock-in-trade	116.48	906.32	(391.04)	(253.36)
	b Cost of Materials Consumed	3604.65	4232.64	6989.48	24892.62
	c Purchase of Stock -in-Trade	-	227.75	-	227.75
	d Employee Benefits Expense	178.09	159.67	156.57	657.74
	e Processing Charges	204.01	242.73	205.68	803.87
	f Power Fuel & Other Utility	71.83	47.94	86.36	347.68
	g Depreciation and amortisation expenses	51.35	57.52	50.50	225.88
	h Other Expenses	289.54	556.01	446.49	2017.58
	Total Expenses :-	4515.95	6430.57	7544.04	28919.76
3	Profit From Operations before other income, Finance Costs & Exceptional Items (1-2)	394.50	583.73	1119.90	3702.41
4	a Other Income	132.25	129.18	106.78	350.65
	b Exchange Gain/(Loss)	3.70	(13.07)	(59.29)	(255.11)
5	Profit from ordinary activities before finance costs & Exceptional Items(3+4)	530.45	699.84	1167.39	3797.96
6	Finance Costs	0.31	3.00	0.06	4.25
7	Profit from ordinary activities after finance costs but before Exceptional Items(5-6)	530.14	696.85	1167.33	3793.71
8	Exceptional Items	-	-	-	-
9	Profit / (Loss) from ordinary activities before Tax (7+8)	530.14	696.85	1167.33	3793.71
10	Tax Expenses	141.00	183.28	365.00	1213.28
11	Net Profit / (Loss) from ordinary activities after Tax (9-10)	389.14	513.57	802.33	2580.43
12	Extraordinary Item (Net of Tax Expenses)	-	-	-	-
13	Profit / (Loss) for the period after Tax (after Extra ordinary items)	389.14	513.57	802.33	2580.43
14	Share of profit / (Loss) of associates	-	-	-	-
15	Minority Interest	-	-	-	-
16	Net Profit(+) / Loss(-) after taxes, minority interest and share of profit of profit / (loss) of associates (13+14+15)	389.14	513.57	802.33	2580.43
17	Paid up Equity Share Capital (Face value of ₹ 5/- each)	1252.80	1252.80	417.60	1252.80
18	Reserves excluding Revaluation Reserves as per Balance sheet of Previous Accounting Year				10674.99
19	Earnings per Share(EPS) Face Value of Rs.5/-				
	Earnings Per Share(before and after Extraordinary items) (not annualised)				
	(a) Basic	1.55	2.05	3.20 #	10.30
	(b) Diluted	1.55	2.05	3.20 #	10.30

- The above Financial Results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their Meeting held on 9th August, 2016.
- The Company's operation fall under single segment namely "Bulk Drugs & Chemicals".
- The above is an extract of the detailed format of Quarterly Financial Results for the Quarter ended on 30th June, 2016, filed with the Stock Exchange under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results on the Stock Exchange website viz . www.bseindia.com and on the Company's website(i.e.) www.anuhpharma.com.
- Corresponding figures of the previous quarter have been regrouped, to make them comparable wherever necessary.
- EPS reported at mark # is after giving effect to the issue of bonus shares in the ratio of 2 bonus shares for each existing share.

Place : Mumbai
Date : 9th AUGUST, 2016

For ANUH PHARMA LIMITED



Managing Director



73-B MITTAL COURT, NARIMAN POINT, MUMBAI 400021, INDIA

TEL.: (91 22) 22842093, 22842159 | FAX: (91 22) 22822743 | E-MAIL: SIMCO@SIMOGUL.COM | WEBSITE: SIMOGUL.COM

LIMITED REVIEW REPORT

**TO THE BOARD OF DIRECTORS OF
ANUH PHARMA LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **Anuh Pharma Limited** ("**Company**") for the period ended on June 30, 2016 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement ("**SRE**") 2400, '*Engagements to Review Financial Statements*' issued by the Institute of Chartered Accountants of India ("**ICAI**"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **S. I. MOGUL & CO.**
Chartered Accountants
Firm Registration No. 106512W



S. I. Mogul

S. I. Mogul
Partner

Membership No. 5572

Mumbai, India: August 9, 2016